Remove 2019 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Pharma within planetary boundaries

European Pharmaceutical Review

The ERA therefore needs teeth – which does not mean it should be a barrier to the authorisation of new medicines – but it should require pharmaceutical companies to minimise harmful effects on the environment, which indirectly also harm our health. cited 23Apr]. Available from: [link]. Steenmeijer M, et al. Lancet Planetary Health.

article thumbnail

The Obesity Drug Development Summit has landed in Europe!

pharmaphorum

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The impact of climate change on the pharma supply chain

Pharmaceutical Technology

Pharmaceutical companies need to be prepared to answer the call for increased demand and supply into new markets, ensuring the proper resources and logistics framework are in place. In addition, a paper published in 2019, concluded that the pharmaceutical industry produced 48.55

article thumbnail

Why demand is rising for secure and climate-controlled gene therapy services

Pharmaceutical Technology

Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Products are stored and packaged in a dedicated suite by a dedicated team,” explains MacNeir.

article thumbnail

A New Regulatory Approach to Drive Sustainable Medicines

ISPE

As such there’s a growing question of how the industry will improve the sustainability profile of its existing medicines and ensure that sustainability is designed into new medicines, such as products, with a reduced environmental risk, greener manufacturing technologies, and recyclable delivery systems and packaging. 9 December 2021.

article thumbnail

Enabling the leaders of the future

pharmaphorum

iii] It’s no longer just about the company, compensation package and secondary benefits (e.g., Mark Larsen is vice president and head of human resources for Europe, Middle East and Africa (EMEA) at Janssen, the Pharmaceutical Companies of Johnson & Johnson. gym membership).

article thumbnail

Evorel patches incl. Evorel Conti Alternative drugs

Druggist

Evorel patches have been subject to shortages since 2019. Theramex bought Evorel range of products from Janssen Pharmaceutical Companies (Johnson & Johnson) in October 2019. Theramex committed to increase manufacturing of Evorel products by investing in an additional manufacturer and additional packaging equipment.